Porhomayon Jahan, Zadeii Gino, Yarahmadi Alireza
VA Western New York Healthcare System, Division of Critical Care and Pain Medicine, Department of Anesthesiology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY 14215, USA.
Case Rep Neurol Med. 2013;2013:451206. doi: 10.1155/2013/451206. Epub 2013 Jul 1.
Myoclonus is not a known side effect of ranolazine. We report a case of myoclonus in a 72-year-old female who underwent cardiac catheterization for angina and was started on ranolazine after the procedure. Two days after ranolazine therapy on 1000 mg per day in divided doses, myoclonus developed, which severely impaired her normal activity. Her symptoms resolved 2 days after discontinuation of ranolazine. Ranolazine was resumed after discharge from hospital with recurrent myoclonus after two days of therapy. The causal relationship between ranolazine and myoclonus was suggested by cessation of myoclonus after ranolazine was discontinued.
肌阵挛并非雷诺嗪已知的副作用。我们报告了一例72岁女性出现肌阵挛的病例,该女性因心绞痛接受了心导管插入术,并在术后开始服用雷诺嗪。在每日分剂量服用1000毫克雷诺嗪治疗两天后,出现了肌阵挛,这严重影响了她的正常活动。停用雷诺嗪两天后,她的症状消失。出院后恢复服用雷诺嗪,治疗两天后又出现了复发性肌阵挛。停用雷诺嗪后肌阵挛停止,提示雷诺嗪与肌阵挛之间存在因果关系。